Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KOD |
---|---|---|
09:32 ET | 972 | 4.79 |
09:42 ET | 2000 | 4.8 |
09:44 ET | 3473 | 4.8 |
09:46 ET | 991 | 4.785 |
09:48 ET | 200 | 4.79 |
09:50 ET | 1350 | 4.85 |
09:51 ET | 252 | 4.84 |
09:53 ET | 100 | 4.84 |
10:04 ET | 100 | 4.84 |
10:06 ET | 987 | 4.85 |
10:08 ET | 300 | 4.85 |
10:09 ET | 200 | 4.825 |
10:13 ET | 700 | 4.85 |
10:15 ET | 368 | 4.87 |
10:18 ET | 1000 | 4.835 |
10:20 ET | 1571 | 4.85 |
10:22 ET | 178 | 4.8268 |
10:24 ET | 500 | 4.835 |
10:26 ET | 100 | 4.835 |
10:27 ET | 1200 | 4.85 |
10:29 ET | 1300 | 4.835 |
10:31 ET | 402 | 4.835 |
10:33 ET | 697 | 4.86 |
10:36 ET | 429 | 4.871 |
10:38 ET | 700 | 4.86 |
10:40 ET | 700 | 4.84 |
10:42 ET | 916 | 4.83 |
10:44 ET | 436 | 4.83 |
10:45 ET | 500 | 4.845 |
10:47 ET | 134 | 4.845 |
10:49 ET | 201 | 4.8301 |
10:51 ET | 4325 | 4.83 |
10:54 ET | 3196 | 4.85 |
10:58 ET | 1000 | 4.85 |
11:02 ET | 700 | 4.845 |
11:03 ET | 700 | 4.845 |
11:05 ET | 400 | 4.845 |
11:07 ET | 1200 | 4.8451 |
11:09 ET | 600 | 4.84 |
11:12 ET | 2710 | 4.835 |
11:16 ET | 300 | 4.84 |
11:18 ET | 200 | 4.84 |
11:20 ET | 100 | 4.845 |
11:21 ET | 500 | 4.845 |
11:23 ET | 7556 | 4.815 |
11:25 ET | 1500 | 4.8451 |
11:27 ET | 400 | 4.85 |
11:34 ET | 1850 | 4.85 |
11:36 ET | 100 | 4.83 |
11:39 ET | 746 | 4.84 |
11:41 ET | 100 | 4.84 |
11:43 ET | 1575 | 4.85 |
11:48 ET | 1030 | 4.85 |
11:52 ET | 326 | 4.85 |
11:56 ET | 225 | 4.85 |
11:59 ET | 200 | 4.85 |
12:06 ET | 641 | 4.85 |
12:08 ET | 1456 | 4.85 |
12:10 ET | 107 | 4.85 |
12:12 ET | 310 | 4.84 |
12:14 ET | 300 | 4.85 |
12:15 ET | 1150 | 4.83 |
12:17 ET | 100 | 4.8299 |
12:19 ET | 100 | 4.84 |
12:21 ET | 800 | 4.86 |
12:28 ET | 2787 | 4.9 |
12:32 ET | 900 | 4.85 |
12:46 ET | 100 | 4.86 |
12:48 ET | 100 | 4.87 |
12:51 ET | 399 | 4.88 |
12:53 ET | 154 | 4.8899 |
12:55 ET | 400 | 4.8712 |
01:02 ET | 600 | 4.87 |
01:04 ET | 100 | 4.86 |
01:09 ET | 700 | 4.86 |
01:15 ET | 3303 | 4.845 |
01:18 ET | 514 | 4.845 |
01:20 ET | 200 | 4.84 |
01:24 ET | 934 | 4.85 |
01:27 ET | 100 | 4.85 |
01:29 ET | 300 | 4.86 |
01:33 ET | 700 | 4.87 |
01:36 ET | 5724 | 4.89 |
01:38 ET | 100 | 4.88 |
01:40 ET | 1000 | 4.8802 |
01:42 ET | 3409 | 4.88 |
01:44 ET | 500 | 4.86 |
01:49 ET | 1500 | 4.865 |
01:51 ET | 2659 | 4.86 |
01:54 ET | 2000 | 4.86 |
01:56 ET | 1908 | 4.85 |
01:58 ET | 100 | 4.86 |
02:02 ET | 5900 | 4.845 |
02:03 ET | 200 | 4.845 |
02:09 ET | 300 | 4.845 |
02:12 ET | 600 | 4.845 |
02:14 ET | 200 | 4.845 |
02:16 ET | 414 | 4.845 |
02:20 ET | 1428 | 4.85 |
02:25 ET | 500 | 4.84 |
02:27 ET | 400 | 4.85 |
02:32 ET | 400 | 4.85 |
02:34 ET | 200 | 4.85 |
02:38 ET | 400 | 4.865 |
02:41 ET | 300 | 4.86 |
02:43 ET | 400 | 4.85 |
02:45 ET | 200 | 4.86 |
02:50 ET | 400 | 4.86 |
02:52 ET | 200 | 4.86 |
02:54 ET | 300 | 4.86 |
02:56 ET | 4505 | 4.85 |
02:57 ET | 202 | 4.85 |
03:01 ET | 900 | 4.855 |
03:03 ET | 300 | 4.86 |
03:08 ET | 113 | 4.85 |
03:12 ET | 200 | 4.88 |
03:14 ET | 700 | 4.86 |
03:15 ET | 200 | 4.855 |
03:17 ET | 200 | 4.855 |
03:19 ET | 600 | 4.855 |
03:21 ET | 1128 | 4.85 |
03:24 ET | 200 | 4.84 |
03:26 ET | 1330 | 4.845 |
03:28 ET | 582 | 4.84 |
03:30 ET | 568 | 4.845 |
03:32 ET | 850 | 4.845 |
03:33 ET | 100 | 4.845 |
03:35 ET | 628 | 4.86 |
03:37 ET | 1400 | 4.8613 |
03:42 ET | 100 | 4.865 |
03:44 ET | 1038 | 4.87 |
03:46 ET | 600 | 4.88 |
03:48 ET | 1080 | 4.87 |
03:50 ET | 600 | 4.87 |
03:51 ET | 921 | 4.87 |
03:53 ET | 3865 | 4.89 |
03:55 ET | 4389 | 4.915 |
03:57 ET | 2572 | 4.92 |
04:00 ET | 64158 | 4.92 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kodiak Sciences Inc | 258.9M | -1.3x | --- |
Inozyme Pharma Inc | 258.2M | -2.6x | --- |
Omeros Corp | 255.5M | -1.3x | --- |
Pyxis Oncology Inc | 262.6M | -3.5x | --- |
Climb Bio Inc | 254.2M | -1.8x | --- |
Lexeo Therapeutics Inc | 264.5M | -2.8x | --- |
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $258.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.24 |
EPS | $-3.77 |
Book Value | $5.06 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.